Today: 26 March 2026
Subscribe
Browse Category

Stock Market 15 March 2025 - 31 May 2025

Austria’s Digital Autobahn: The State of Internet Access in 2025 (Including Satellite!)

Austria’s Digital Autobahn: The State of Internet Access in 2025 (Including Satellite!)

By 2025, only 17% of Austria’s 1.9 million fiber-ready homes have active subscriptions. Vienna has over 750,000 fiber connections available. A1 Telekom Austria, Magenta Telekom, and Drei/Tele2 dominate broadband, with A1 holding about 30–31% of fixed and 37% of mobile subscribers. 4G covers 99% of the population; 5G reached 85% by 2023, targeting full coverage by end of 2025.
31 May 2025
···
Internet Access in Kiribati: Bridging the Digital Divide Across Remote Pacific Islands

Internet Access in Kiribati: Bridging the Digital Divide Across Remote Pacific Islands

About 73,300 people in Kiribati used the internet as of January 2024, covering 54.4% of the population. The country relies entirely on satellite links for connectivity, with no submarine fiber cable in place. The East Micronesia Cable System is under construction and expected to connect Tarawa to Guam by 2025. Starlink has around 1,500 user terminals in South Tarawa, though not yet officially licensed.
22 March 2025
·
1 … 1,362 1,363 1,364

Stock Market Today

  • Legend Biotech (LEGN) Shares Underpriced Amid Profitability Push, Says Vestra
    March 26, 2026, 12:24 PM EDT. Legend Biotech (LEGN) shares closed at $17.60, showing mixed returns recently with a 30-day gain of 9.74% and a one-year total shareholder return of 50.27%. Despite posting a net loss of $296.8 million on $1.03 billion revenue, analysts see potential in the company's shift toward profitability, guided for 2026. Vestra values LEGN at $54.55, signaling significant upside from the current price. Key to this outlook is the Q4 2025 earnings beat and progress in injectable cell therapies expected in late 2026, which could disrupt traditional ex vivo manufacturing. Risks include manufacturing setbacks and competitive pressures on Carvykti sales. Investors eyeing biotech growth amid AI-driven drug development should weigh these factors before acting.
Go toTop